Humalog (R) Mix25 (TM) offers better mealtime glycemic control in patientswith type 1 or type 2 diabetes

To compare the postprandial glucodynamics of Humalog(R) Mix25,(TM) (Humalog (R) Mix75/25 in the US; Mix25), to human insulin 30/70 (Humulin(R) 70/30 in the US; 30/70) in patients with type 1 or type 2 diabetes. Ninety-three patients with type 1 diabetes and 84 patients with type 2 diab etes were evaluated in two separate but identical protocols using a randomi zed, multicenter, double-blind, crossover design. Patients consumed test me als 5 minutes after equal doses of Mix25 or 30/70. Plasma glucose was measu red at baseline and 15 minute intervals for 4 hours after the meal. Two-hou r postprandial glucose (2pp), L-hour glucose excursion (2pp(ex)), glucose v ersus time area under the curve 0 to 4 hours (AUC(0-4)) and glucose excursi on area under the curve 0 to 2 and 0 to 4 hours (AUCex(0-2), AUCex(0-4)) we re calculated. For the combined patient population, Mix25 resulted in significantly lower 2pp (12.45 +/- 3.59 vs. 13.47 +/- 3.62 mmol/L; p < 0.001), AUC(0-4) (44.45 +/- 12.20 vs. 47.25 +/- 11.97 mmol.h/L; p < 0.001), and glucose excursion p arameters: 2pp(ex) (3.20+/- 2.72 vs. 4.40+/- 2.81 mmol/L; p<0.001), AUCex(0 -2) (5.45 +/- 3.15 vs 6.60 +/- 3.13 mmol.h/L; p<0.001), and AUCex(0-4) (7.5 7 +/- 8.37 vs. 11.02 +/- 8.47 mmol.h/L; p < 0.001) compared to 30/70. Furth er analysis of the treatment by type of diabetes indicated that Mix25 provi ded nearly identical glucose excursion responses in type 1 and type 2 diabe tes up to 2 hours after the test meal, in contrast to 30/70. Pre-meal injection of Mix25 resulted in lower postprandial blood glucose le vels compared to 30/70. The postprandial blood glucose response following M ix25 was similar in patients with either type 1 or type 2 diabetes.